Topics presented at the 16th IGPA conference on generics

INICIO/Congresos | Posted 17/01/2014 post-comment0 Post your comment

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

Conference V14A17

A review of the market and trends in Europe and North America revealed that the majority of medicines consumed in Canada, Europe and the US are generics. Biosimilars were also highlighted as being key to increase patients’ access to innovative treatments. Trends for the generics market in Canada, Europe and North America were the increased uptake of generics and cost reductions, as well as the consolidation and globalization of generics companies.

The importance for Europe to adopt a manufacturing provision allowing generics companies to develop their products during the period covered by the Supplementary Protection Certificate (SPC) was highlighted. Other intellectual property topics covered were settlements between brand-name and generics companies and patent pools.

A review of the market and trends in Asia showed China to be one of the most significant markets for off-patent originators and generics. A review of the market and trends in emerging markets such as Brazil and Mexico showed the high use of generics and the great potential for biosimilars in these countries. A review of the Middle East showed how inequities in healthcare provisions contributed to the Arab Spring.

The importance of using an international approach in order to ensure the quality of starting materials for pharmaceuticals was highlighted. How regulatory agencies, such as EMA and FDA, were working towards increased cooperation and convergence of regulatory processes was outlined. The actions of International Generic Drug Regulators (IGDRP) to foster international collaboration and convergence of regulations was discussed. The willingness of Europe to adopt an ‘information-sharing’ model and accept data from Competent Authorities from third countries was also presented.

Finally, the impact of trade agreements on generics was discussed. In most cases these trade agreements were seen to have a negative impact, in that they generally increased patent protection for brand-name drugs, delaying the introduction of generics.

Related article

EGA pushes for increased focus on generics and biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: IGPA

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010